Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M285,470Revenue $M71,312Net Margin (%)23.3Z-Score5.3
Enterprise Value $M270,968EPS $4.8Operating Margin %28.1F-Score7
P/E(ttm))18.7Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %3.5Quick Ratio2.1Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-0.9Current Ratio2.5Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %9.0ROA % (ttm)15.9Higher Current Ratio y-yY
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)28.2Less Shares Outstanding y-yY
Payout Ratio %50.0Shares Outstanding M2,820ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Brian Rogers 2014-09-304,633,0000.161.8
JNJ Yacktman Fund 2014-09-303,900,0000.143.6-3.7%
JNJ Yacktman Focused Fund 2014-09-303,100,0000.113.5-6.06%
JNJ John Rogers 2014-06-30522,7270.020.67+42.46%
JNJ Richard Pzena 2014-06-301,155,6660.040.67+33.12%
JNJ Ken Fisher 2014-06-3010,448,4480.372.3+4.72%
JNJ James Barrow 2014-06-3017,065,2300.612.4+0.66%
JNJ Jean-Marie Eveillard 2014-06-301,623,4820.060.41+0.37%
JNJ Ruane Cunniff 2014-06-3076,01200.04+0.29%
JNJ Yacktman Fund 2014-06-304,050,0000.143.6
JNJ Brian Rogers 2014-06-304,633,0000.161.7
JNJ Richard Snow 2014-06-303,24500.01
JNJ Michael Price 2014-06-3035,00000.45
JNJ Tom Gayner 2014-06-30574,2000.021.7
JNJ Dodge & Cox 2014-06-3038,62500
JNJ Richard Perry 2014-06-30342,2770.010.99
JNJ Warren Buffett 2014-06-30327,1000.010.03
JNJ Prem Watsa 2014-06-3084,70000.61
JNJ PRIMECAP Management 2014-06-3012,242,4200.431.4-0.48%
JNJ Tweedy Browne 2014-06-304,196,2240.159.4-1.71%
JNJ Donald Yacktman 2014-06-309,045,9020.323.8-5.5%
JNJ Mario Gabelli 2014-06-30373,1860.010.2-5.54%
JNJ Yacktman Focused Fund 2014-06-303,300,0000.123.5-13.16%
JNJ Robert Olstein 2014-06-3087,00001.2-20.91%
JNJ John Hussman 2014-06-301,32500.01-50%
JNJ George Soros 2014-06-3050,00000.04-51.22%
JNJ HOTCHKIS & WILEY 2014-06-301,426,6140.050.53-63.73%
JNJ Ray Dalio 2014-06-3065,89300.05-74.94%
JNJ Joel Greenblatt 2014-06-30000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-3.61view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.3-3.78view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.050.31view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.157.74view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.399.82view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.687.13view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.48.61view
Caruso Dominic JVP, Finance; CFO 2013-07-18Sell30,000$90.3111.13view
CULLEN JAMESDirector 2013-05-07Sell4,929$85.417.52view
LINDQUIST SUSAN LDirector 2012-12-07Sell7,600$70.0243.33view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Bill Frels Comments on Johnson & Johnson Oct 20 2014 
    Bill Frels' Mairs & Power Growth Fund Q3 2014 Commentary Oct 20 2014 
    What Have We Really Lost? Oct 20 2014 
    The Key Drivers For Johnson & Johnson Oct 15 2014 
    Alios BioPharma Presented Positive Results of Its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Ch Oct 15 2014 
    Don't Forget: Buy And Hold Is Not Buy And Forget Oct 14 2014 
    Sure Bets: Slow-Changing Industries for Long-Term Investors Oct 01 2014 
    "A Unique Period of Time," Revisited Sep 22 2014 
    The 4% Rule Examined Sep 11 2014 
    Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 

    More From Our Partners
    What Have We Really Lost? Oct 20 2014 - SEEKINGALPHA

    More From Other Websites
    J&J aims for 1 million Ebola vaccine doses in 2015 Oct 22 2014
    J&J Says 250,000 Ebola Vaccine Doses to Be Ready by May Oct 22 2014
    J&J and Bavarian Nordic expand production of an Ebola vaccine program Oct 22 2014
    Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly... Oct 22 2014
    [$$] Johnson & Johnson to Begin Testing Ebola Vaccine in January Oct 22 2014
    Jury deliberations begin in first trial over DePuy's Pinnacle hips Oct 21 2014
    J&J Ignored Reports Pinnacle Hip Implants Failed: Lawyer Oct 21 2014
    Vaccines, Medical Oxygen, and Helping the Ebola Crisis Oct 21 2014
    Tens of thousands expected to get Ebola vaccines from January - WHO Oct 21 2014
    Tens of thousands expected to get Ebola vaccines from January - WHO Oct 21 2014
    Tens of thousands expected to get Ebola vaccines from January - WHO Oct 21 2014
    Video: Celgene Reports More Good Crohn's Drug Data Oct 21 2014
    Ebola Vaccine Trials Carry Risks for Companies in Chase Oct 20 2014
    Celgene's Crohn's Disease Drug Hits Its Marks Oct 20 2014
    [video] Surviving Wall Street's wild ride Oct 17 2014
    Surviving Wall Street's wild ride Oct 17 2014
    [$$] Covidien Wins Patent Injunction Against J&J Oct 17 2014
    [video] Wild ride for widely-held stocks Oct 17 2014
    [video] Signs of stability? Check out widely-held stocks Oct 17 2014
    Signs of stability? Check out widely-held stocks Oct 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK